The Phase 1, open-label, randomised, clinical trial will be conducted at three clinical sites in Northern California, US.
The study will enroll 40 postmenopausal women between the ages of 40 and 65 years, who will be randomised to one of two doses of Menerba and treated for 28 days.
The primary goal of the study is to evaluate the safety of two doses MF101 after 4 weeks of treatment.
Menerba is an estrogen receptor beta (ER-b) selective drug manufactured from botanical sources, designed for the treatment of hot flushes associated with menopause.